Clinical trials: Residual Disease
Vestibular Schwannoma
Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function
The purpose of the study is to determine whether vestibular and postural compensation following schwannoma surgery is improved by ablating vestibular function prior to surgery, even if vestibular function is absent according to…
- Trial name
- NCT02415257
- Testing
- Gentamicin
- Where
- Sweden
- Sponsor
- Lund University
AML (Acute Myelogenous Leukemia)
VEN+IDAC vs IDAC in AML
This study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment…
- Trial name
- NCT07537257
- Testing
- Ventoclax, Cytarabine
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Guangdong Second Provincial General Hospital
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to gilteritinib (ASP2215) for patients with FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed or refractory acute myeloid leukemia (AML) or with FLT3-mutated AML in…
- Trial name
- NCT03409081
- Testing
- gilteritinib
- Where
- 6 sites in Australia, Italy and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Asthma
Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate
This study is to find out if an Extra Virgin Olive-Oil-based Water (EVOOW) mix, removes more Fluticasone Propionate (FP) from the mouth than Water alone.
- Trial name
- EVOOW (NCT07664527)
- Testing
- Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Cutaneous Melanoma, Melanoma Stage IV
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Clear-Me is a biomarker-driven phase II study that tests whether the combination anti- lymphocyte-activation gene-3 (LAG3)/anti-programmed cell death protein 1(PD-1) inhibition Bristol-Myers Squibb (BMS986213) is superior to…
- Conditions
- Cutaneous Melanoma, Melanoma Stage IV, Mucosal Melanoma
- Trial name
- ClearMe (NCT06319196)
- Testing
- Opdualag, Nivolumab
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- University Health Network, Toronto
Esophageal Cancer, Photodynamic Therapy
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
The objective of the present clinical trial is to assess the efficacy of photodynamic therapy (PDT) employing hematoporphyrin injection in the management of recurrent or residual superficial esophageal carcinoma.
- Trial name
- NCT06437288
- Testing
- photodynamic therapy
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Acute Myeloid Leukemia
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Ceplene/IL-2 remission maintenance therapy has been shown to significantly prolong Leukemia Free Survival in patients with Acute Myeloid Leukemia (AML) in first complete remission.
- Trial name
- NCT01347996
- Testing
- histamine dihydrochloride and IL-2
- Where
- Sweden
- Volunteers
- 84 people
- Sponsor
- Cytovia, Inc.
Mantle Cell Lymphoma
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
This is an observational study aimed to analyze the effectiveness of treatment of patients with newly dg. mantle cell lymphoma not eligible for high-dose therapy and autologous stem cell transplantation.
- Trial name
- NCT03054883
- Volunteers
- 73 people
- Sponsor
- Czech Lymphoma Study Group
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously), Bortezomib (BTZ), Len (lenalidomide)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain.
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Minimal Residual Disease
- Trial name
- NCT06536959
- Testing
- PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Beijing 302 Hospital
Large B-cell Lymphoma
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
The goal of the main clinical research study is to learn if treatment with a chimeric antigen receptor (CAR) T-cell therapy called lisocabtagene maraleucel (liso-cel) can help to prevent recurrence of large B-cell cell lymphoma…
- Trial name
- NCT07316010
- Testing
- Leukapheresis, Lymphodepleting Chemotherapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
This phase I clinical trial studies the side effects and best dose of CD19-specific T-cells in treating patients with lymphoid malignancies that have spread to other places in the body and usually cannot be cured or controlled…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD19 Positive
- Trial name
- NCT02529813
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Anisometropic Amblyopia, Accommodation Disorder
Accommodation Response in Hypermetropic Anisometropia (ARIHA Study)
Anisometropic amblyopia is when one eye has a much stronger glasses prescription than the other, causing poor vision in one eye, even with glasses, because the brain favours the better-seeing eye.
- Trial name
- ARIHA (NCT06286410)
- Testing
- Bespoke glasses prescription worn during amblyopia treatment.
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University of Sheffield
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00003413
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia, Minimal Residual Disease
Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia
Study purpose is to assess the prognostic role of Minimal Residual Disease (defined as medullary expression of WT1 gene), performed at Baseline and during treatment according to clinical practice.
- Conditions
- Acute Myeloid Leukemia, Minimal Residual Disease, Wilms Tumor
- Trial name
- LAM-MMR (NCT02714790)
- Volunteers
- 281 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
B Acute Lymphoblastic Leukemia, Minimal Residual Disease
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
This phase II trial studies how well pembrolizumab works in treating small amounts of cancer cells that remain after attempts to remove the cancer has been made in patients with acute lymphoblastic leukemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Recurrent Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT02767934
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Hematologic Malignancy
Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)
This is an open-labelled and non-controlled Phase I/II clinical trial, evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after umbilical cord blood (UCB)…
- Trial name
- HTLP-ONCO (NCT04707300)
- Testing
- Human T Lymphoid Progenitor (HTLP) injection
- Where
- 5 sites in France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetic Macular Edema
Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab
This is an open-label, Phase I/II study of intravitreally administered ranibizumab either 0.5-mg and/or 2.0-mg in subjects with clinical, angiographic, and ocular coherence tomography (OCT) evidence of diabetic retinopathy with…
- Trial name
- REEF (NCT01292798)
- Testing
- Ranibizumab
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- California Retina Consultants
Chronic Periodontitis
Clinical Efficacy Of 810 Nanometer Diode Laser As An Adjunct To Mechanical Periodontal Treatment Of Residual Periodontal Pockets
Background: Aim of this randomized controlled parallel-designed study was to evaluate the effects of diode laser as an adjunct to mechanical periodontal treatment on clinical parameters and gingival crevicular fluid (GCF) volume…
- Trial name
- NCT02531555
- Testing
- 810 Nanometer Wavelenght GaAlAs Diode Laser, Gracey curettes
- Where
- Turkey (Türkiye)
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Marmara University
Diabetes Mellitus, Type 2
Digital Therapeutic Based Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy
Randomized, controlled, multicenter, pragmatic, pivotal trial with open-label extension evaluating the hypothesis that BT-001 an investigational digital therapeutic intended to help patients with type 2 diabetes improve their…
- Trial name
- BRIGHT (NCT05266625)
- Testing
- BT-001, Control App
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- Better Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.